Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-11-26
2010-06-22
Vivlemore, Tracy (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S023100, C536S024500
Reexamination Certificate
active
07741308
ABSTRACT:
The invention relates to compositions and methods for interfering with the DNA repair of double strand breaks (DSBs). The invention discloses novel double-stranded nucleic acid molecules. that act as baits and hijack the holocomplex of enzymes responsible of DNA DSB sensing, signaling and/or repair pathways, in particular the non homologous end joining (NHEJ) pathway of DSB repair.The invention discloses the use of these molecules as adjuvant compositions to be used in association with a DNA breaking treatment, particularly radiotherapy or chemotherapy, in combination with a pharmaceutically acceptable carrier, in an efficient amount to be introduced in the tumor cell nuclei in order to neutralize transiently their DNA repair capacity and trigger their death.
REFERENCES:
patent: 7060690 (2006-06-01), Klem
patent: 2003/0176376 (2003-09-01), Klem
patent: 2007/0111961 (2007-05-01), Dutreix et al.
patent: 2007/0197458 (2007-08-01), Dutreix et al.
patent: 0 978 561 (2000-02-01), None
patent: WO 94/01550 (1994-01-01), None
patent: WO 03/069306 (2003-08-01), None
patent: WO 03/070914 (2003-08-01), None
International Search Report of PCT/EP2004/012857, mailed Mar. 4, 2005.
Partial European Search Report of EP 03 29 2666, completed May 14, 2004.
Omori et al., “Suppression of a DNA doublepstrand break repair gene,Ku70, increases radio- and chemosensitivity in a human lung carcinoma cell line”, DNA Repair, pp. 299-310.
Ohnishi et al., “In vitro and in vivo potentiation of radiosensitivity of malignant gliomas by antisense inhibition of the RAD51 gene”, Biochemical and Biophysical Research Communications, vol. 245, No. 2, 1998, pp. 319-324.
Verrelle et al., “Modulation de la reponse cellulaire aux radiations ionisantes: vers de nouvelles cibles moleculaires?”, Cancer/Radiother, vol. 1, 1997, pp. 484-493.
Li et al, “Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection”, The EMBO Journal 2001, vol. 20, No. 12, pp. 3272-3281.
Jackson et al, “Sensing and repairing DNA double-strand breaks”, Carcinogenesis 2002, vol. 23, pp. 687-696.
Marthinet et al, “Modulation of the typical multidrug resistance henotype by targeting the MED-1 region of human MDR1 promoter”, Gene Therapy (2000) 7, 1224-1233.
Opalinska et al, “Nucleic-Acid Therapeutics: Basic Principles and Recent Applications”, Nature Reviews, vol. 1, Jul. 2002, pp. 503-514.
Dutreix Marie
Sun Jian-Sheng
Centre National de la Recherche Scientifique "CNRS"
Institut Curie
Institut National de la Sante Et de la Recherche Medicale (INSER
Museum National d'Historie Naturelle
Nixon & Vanderhye P.C.
LandOfFree
DBAIT and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DBAIT and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DBAIT and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4221956